Involvement of CYP1A2 in Mexiletine Metabolism

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1998 Aug 5

PMID 9690950

Citations 11

Authors

M Nakajima

K Kobayashi

N Shimada

S Tokudome

T Yamamoto

Y Kuroiwa

Affiliations

Soon will be listed here.

Abstract

Aims: Mexiletine has been reported to be hydroxylated by cytochrome P450 2D6 (CYP2D6) in humans. However, the involvement of CYP1A2 in the metabolism of mexiletine has been proposed based on the interaction with theophylline which is mainly metabolized by CYP1A2. The aim of this study was to clarify the role of human CYP1A2 in mexiletine metabolism.

Methods: Human CYP isoforms involved in mexiletine metabolism were investigated using microsomes from human liver and B-lymphoblastoid cells expressing human CYPs. The contributions of CYP1A2 and CYP2D6 to mexiletine metabolism were estimated by the relative activity factor (RAF).

Results: Mexiletine p- and 2-hydroxylase activities in human liver microsomes were inhibited by ethoxyresorufin and furafylline as well as quinidine. Mexiletine p- and 2-hydroxylase activities in microsomes from nine human livers correlated significantly with bufuralol 1'-hydroxylase activity (r = 0.907, P < 0.001 and r = 0.886, P < 0.01, respectively). Microsomes of B-lymphoblastoid cells expressing human CYP1A2 exhibited lower mexiletine p- and 2-hydroxylase activities than those expressing human CYP2D6. It was estimated by RAF that the major isoform involved in mexiletine metabolism was CYP2D6, and the contribution of CYPIA2 to both mexiletine p- and 2-hydroxylase activities was 7-30% in human liver microsomes. However, the Km values of the expressed CYP1A2 (approximately 15 microM) were almost identical with those of the expressed CYP2D6 (approximately 22 microM) and human liver microsomes.

Conclusions: Mexiletine is a substrate of CYP1A2. The data obtained in this study suggest that the interaction of mexiletine with theophylline might be due to competitive inhibition of CYP1A2.

Citing Articles

study on the effect of peucedanol on the activity of cytochrome P450 enzymes.

Zhang C, Li Y, Yin C, Zheng J, Liu G Pharm Biol. 2022; 59(1):935-940.

PMID: 35294326 PMC: 8274509. DOI: 10.1080/13880209.2021.1944223.

Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial.

Heatwole C, Luebbe E, Rosero S, Eichinger K, Martens W, Hilbert J Neurology. 2020; 96(2):e228-e240.

PMID: 33046619 PMC: 7905778. DOI: 10.1212/WNL.0000000000011002.

Interactions of Mexiletine with Novel Antiepileptic Drugs in the Maximal Electroshock Test in Mice: An Isobolographic Analysis.

Wroblewska D, Rudkowska M, Banach M, Borowicz-Reutt K Neurochem Res. 2018; 43(10):1887-1896.

PMID: 30117096 PMC: 6182375. DOI: 10.1007/s11064-018-2606-8.

Therapeutic drug monitoring of mexiletine at a large academic medical center.

Nei S, Danelich I, Lose J, Leung L, Asirvatham S, McLeod C SAGE Open Med. 2016; 4:2050312116670659.

PMID: 27708780 PMC: 5034464. DOI: 10.1177/2050312116670659.

The in vitro metabolism of desglymidodrine, an active metabolite of prodrug midodrine by human liver microsomes.

Akimoto M, Iida I, Itoga H, Miyata A, Kawahara S, Kohno Y Eur J Drug Metab Pharmacokinet. 2004; 29(3):179-86.

PMID: 15537169 DOI: 10.1007/BF03190595.

References

Sinjari T, Tornwall U, Darnerud P . Induction of 7-ethoxyresorufin-O-deethylase (EROD) activity in mice foetuses by the PCB-congener 3,3',4,4'-tetrachlorobiphenyl. Xenobiotica. 1993; 23(2):107-14. DOI: 10.3109/00498259309059366. View

Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich F . Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994; 270(1):414-23. View

Penman B, Chen L, Gelboin H, Gonzalez F, Crespi C . Development of a human lymphoblastoid cell line constitutively expressing human CYP1A1 cDNA: substrate specificity with model substrates and promutagens. Carcinogenesis. 1994; 15(9):1931-7. DOI: 10.1093/carcin/15.9.1931. View

Yamazaki H, Guo Z, Persmark M, Mimura M, Inoue K, Guengerich F . Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol Pharmacol. 1994; 46(3):568-77. View

Clarke S, Ayrton A, Chenery R . Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica. 1994; 24(6):517-26. DOI: 10.3109/00498259409043254. View

Ha H, Chen J, Freiburghaus A, Follath F . Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol. 1995; 39(3):321-6. PMC: 1365010. DOI: 10.1111/j.1365-2125.1995.tb04455.x. View

Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T . Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther. 1997; 280(2):927-33. View

Kobayashi K, Nakajima M, Chiba K, Yamamoto T, Tani M, Ishizaki T . Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol. 1998; 45(4):361-8. PMC: 1873964. DOI: 10.1046/j.1365-2125.1998.t01-1-00692.x. View

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

10.

Kamataki T, Kitagawa H . Effects of lyophilization and storage of rat liver microsomes on activity of aniline hydroxylase, contents of cytochrome b5 and cytochrome p-450 and aniline-induced p-450 difference spectrum. Jpn J Pharmacol. 1974; 24(2):195-203. DOI: 10.1254/jjp.24.195. View

11.

Prescott L, Pottage A, Clements J . Absorption, distribution and elimination of mexiletine. Postgrad Med J. 1977; 53 Suppl 1:50-5. View

12.

BECKETT A, Chidomere E . The distribution, metabolism and excretion of mexiletine in man. Postgrad Med J. 1977; 53 Suppl 1:60-8. View

13.

Johannesen K, Depierre J . Measurement of cytochrome P-450 in the presence of large amounts of contaminating hemoglobin and methemoglobin. Anal Biochem. 1978; 86(2):725-32. DOI: 10.1016/0003-2697(78)90800-x. View

14.

Campbell N, Kelly J, Adgey A, Shanks R . The clinical pharmacology of mexiletine. Br J Clin Pharmacol. 1978; 6(2):103-8. PMC: 1429421. DOI: 10.1111/j.1365-2125.1978.tb00833.x. View

15.

Woosley R, Wang T, Stone W, Siddoway L, Thompson K, Duff H . Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. Am Heart J. 1984; 107(5 Pt 2):1058-65. DOI: 10.1016/0002-8703(84)90175-3. View

16.

Gillis A, Kates R . Clinical pharmacokinetics of the newer antiarrhythmic agents. Clin Pharmacokinet. 1984; 9(5):375-403. DOI: 10.2165/00003088-198409050-00001. View

17.

Gilbert M, Turgeon J, LeBlanc P . Effect of cigarette smoking on mexiletine kinetics. Clin Pharmacol Ther. 1985; 37(6):638-43. DOI: 10.1038/clpt.1985.103. View

18.

Williams F, Mutch E, Woodhouse K, Lambert D, Rawlins M . Ethoxyresorufin O-deethylation by human liver microsomes. Br J Clin Pharmacol. 1986; 22(3):263-8. PMC: 1401137. DOI: 10.1111/j.1365-2125.1986.tb02885.x. View

19.

Kronbach T, Mathys D, Gut J, Catin T, Meyer U . High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem. 1987; 162(1):24-32. DOI: 10.1016/0003-2697(87)90006-6. View

20.

Robson R, Matthews A, Miners J, McManus M, Meyer U, Hall P . Characterisation of theophylline metabolism in human liver microsomes. Br J Clin Pharmacol. 1987; 24(3):293-300. PMC: 1386249. DOI: 10.1111/j.1365-2125.1987.tb03172.x. View